1. Scrip

Recent Financings of Private Companies (12/2008)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

Oct.—Beijing Chemclin Biotech (products to test for infectious diseases or tumors) has raised $16.5mm through the closing of its Series B venture round. New investor China Healthcare Partnership (managed by MC China) led the financing and was joined by current backers SB China Venture Capital, Siemens Venture Capital, and WI Harper. China eCapital was the placement agent.

The company, which was established in 1999, is developing diagnostics, including chemiluminescence immunoassay systems, clinical chemistry assay kits, and radioimmunoassay...

More from Archive

More from Scrip

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By Mandy Jackson

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.